Cargando…

Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study

Hepatocellular carcinoma (HCC) remains a global challenge due to its high morbidity and mortality rates as well as poor response to treatment. Local combined systemic therapy is widely used in the treatment of unresectable hepatocellular cancer (uHCC). This retrospective study was to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ziqiang, Yang, Faji, Zhang, Ye, Wang, Jianlu, Ni, Qingqiang, Zhu, Huaqiang, Zhou, Xu, Gao, Hengjun, Lu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798199/
https://www.ncbi.nlm.nih.gov/pubmed/36591442
http://dx.doi.org/10.3389/fonc.2022.1029951
_version_ 1784860856331272192
author Han, Ziqiang
Yang, Faji
Zhang, Ye
Wang, Jianlu
Ni, Qingqiang
Zhu, Huaqiang
Zhou, Xu
Gao, Hengjun
Lu, Jun
author_facet Han, Ziqiang
Yang, Faji
Zhang, Ye
Wang, Jianlu
Ni, Qingqiang
Zhu, Huaqiang
Zhou, Xu
Gao, Hengjun
Lu, Jun
author_sort Han, Ziqiang
collection PubMed
description Hepatocellular carcinoma (HCC) remains a global challenge due to its high morbidity and mortality rates as well as poor response to treatment. Local combined systemic therapy is widely used in the treatment of unresectable hepatocellular cancer (uHCC). This retrospective study was to investigate the prognostic effect and prognostic factors of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICIs) in the treatment of uHCC. A retrospective analysis of 171 patients with uHCC was performed in our hospital from April 27, 2015 to October 18, 2021. According to different treatment options, patients were divided into TACE group (n=45), TACE+TKI group (n=76) and TACE+TKI+ICIs group (n=50). In this study, we found that, the median overall survival (mOS) of TACE+TKI+ICIs group was significantly better than TACE+TKI group and TACE group [24.1 (95% CI 15.1-33.1) months vs 14.9 (95% CI 10.7-19.1) months vs 11.4 (95% CI 8.4-14.5) months, hazard ratio (HR) 0.62; 95% CI 0.47-0.81; P=0.002]. A visible difference in the median progression-free survival (mPFS) interval between the groups was discovered [10.6 (95% CI6.5-14.7) months in TACE+TKI+ICIs group vs. 6.7 (95% CI 5.5-7.9) months in the TACE+TKI group vs. 6 (95% CI 2.3-9.7) months in the TACE group (HR 0.66; 95% CI 0.53-0.83; P<0.001)]. The objective response rates (ORR) in the TACE group, TACE+TKI group, and TACE+TKI+ICIs group were 31.1%, 35.5%, and 42%, and the disease control rate (DCR) were 51.1%, 65.8%, and 80%. There were no adverse events (AEs) of arthralgia, diarrhea, rash, and pruritus in the TACE group. The incidence of grade 3 AEs (Hypertension) in the TACE+TKI+ICIs group was significantly higher than that in TACE+TKI and TACE groups (28% vs 17.1% vs 6.7%, P=0.024), and secondly, the morbidity of rash and pruritus in the TACE+TKI+ICIs group was apparently higher than that in the TACE+TKI group (P<0.05). Multivariate analysis showed that ECOG-PS 2 (HR=2.064, 95%CI 1.335-3.191, P=0.001), Hepatitis B virus (HR=2.539, 95%CI 1.291-4.993, P=0.007), AFP≥400 ng/ml (HR= 1.72, 95%CI 1.12-2.643, P=0.013), neutrophil-lymphocyte ratio (NLR) ≥2.195 (HR=1.669, 95%CI 1.073-2.597, P=0.023) were independent risk factors for OS in uHCC patients. So, TACE+TKI+ICIs therapy can prolong the OS and improve the prognosis of patients effectively, with a well-characterized safety profile.
format Online
Article
Text
id pubmed-9798199
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97981992022-12-30 Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study Han, Ziqiang Yang, Faji Zhang, Ye Wang, Jianlu Ni, Qingqiang Zhu, Huaqiang Zhou, Xu Gao, Hengjun Lu, Jun Front Oncol Oncology Hepatocellular carcinoma (HCC) remains a global challenge due to its high morbidity and mortality rates as well as poor response to treatment. Local combined systemic therapy is widely used in the treatment of unresectable hepatocellular cancer (uHCC). This retrospective study was to investigate the prognostic effect and prognostic factors of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICIs) in the treatment of uHCC. A retrospective analysis of 171 patients with uHCC was performed in our hospital from April 27, 2015 to October 18, 2021. According to different treatment options, patients were divided into TACE group (n=45), TACE+TKI group (n=76) and TACE+TKI+ICIs group (n=50). In this study, we found that, the median overall survival (mOS) of TACE+TKI+ICIs group was significantly better than TACE+TKI group and TACE group [24.1 (95% CI 15.1-33.1) months vs 14.9 (95% CI 10.7-19.1) months vs 11.4 (95% CI 8.4-14.5) months, hazard ratio (HR) 0.62; 95% CI 0.47-0.81; P=0.002]. A visible difference in the median progression-free survival (mPFS) interval between the groups was discovered [10.6 (95% CI6.5-14.7) months in TACE+TKI+ICIs group vs. 6.7 (95% CI 5.5-7.9) months in the TACE+TKI group vs. 6 (95% CI 2.3-9.7) months in the TACE group (HR 0.66; 95% CI 0.53-0.83; P<0.001)]. The objective response rates (ORR) in the TACE group, TACE+TKI group, and TACE+TKI+ICIs group were 31.1%, 35.5%, and 42%, and the disease control rate (DCR) were 51.1%, 65.8%, and 80%. There were no adverse events (AEs) of arthralgia, diarrhea, rash, and pruritus in the TACE group. The incidence of grade 3 AEs (Hypertension) in the TACE+TKI+ICIs group was significantly higher than that in TACE+TKI and TACE groups (28% vs 17.1% vs 6.7%, P=0.024), and secondly, the morbidity of rash and pruritus in the TACE+TKI+ICIs group was apparently higher than that in the TACE+TKI group (P<0.05). Multivariate analysis showed that ECOG-PS 2 (HR=2.064, 95%CI 1.335-3.191, P=0.001), Hepatitis B virus (HR=2.539, 95%CI 1.291-4.993, P=0.007), AFP≥400 ng/ml (HR= 1.72, 95%CI 1.12-2.643, P=0.013), neutrophil-lymphocyte ratio (NLR) ≥2.195 (HR=1.669, 95%CI 1.073-2.597, P=0.023) were independent risk factors for OS in uHCC patients. So, TACE+TKI+ICIs therapy can prolong the OS and improve the prognosis of patients effectively, with a well-characterized safety profile. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9798199/ /pubmed/36591442 http://dx.doi.org/10.3389/fonc.2022.1029951 Text en Copyright © 2022 Han, Yang, Zhang, Wang, Ni, Zhu, Zhou, Gao and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Han, Ziqiang
Yang, Faji
Zhang, Ye
Wang, Jianlu
Ni, Qingqiang
Zhu, Huaqiang
Zhou, Xu
Gao, Hengjun
Lu, Jun
Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
title Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
title_full Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
title_fullStr Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
title_full_unstemmed Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
title_short Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
title_sort prognostic efficacy and prognostic factors of tace plus tki with icis for the treatment of unresectable hepatocellular carcinoma: a retrospective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798199/
https://www.ncbi.nlm.nih.gov/pubmed/36591442
http://dx.doi.org/10.3389/fonc.2022.1029951
work_keys_str_mv AT hanziqiang prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT yangfaji prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT zhangye prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT wangjianlu prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT niqingqiang prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT zhuhuaqiang prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT zhouxu prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT gaohengjun prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT lujun prognosticefficacyandprognosticfactorsoftaceplustkiwithicisforthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy